Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program

ConclusionsNSC 750854 has a unique spectrum of antitumor activity compared with other agents tested by the PPTP as it induces regression in tumor models with limited sensitivity to most agents tested to date. Given the promising level of activity observed for NSC 750854 against PPTP preclinical models, further exploration of its mechanism of action is warranted.

Source: Pediatric Blood and Cancer - November 24, 2015 Category: Cancer & Oncology Authors: Richard Gorlick, E. Anders Kolb, Stephen T. Keir, John M. Maris, Richard B. Lock, Hernan Carol, C. Patrick Reynolds, Min H. Kang, Catherine A. Billups, Jerry Collins, Dias Kurmashev, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith Tags: RESEARCH ARTICLE Source Type: research